ImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC boosted its holdings in ImmunityBio, Inc. (NASDAQ:IBRX) by 43.4% during the fourth quarter, HoldingsChannel reports. The fund owned 9,393 shares of the company’s stock after buying an additional 2,844 shares during the period. Tower Research Capital LLC TRC’s holdings in ImmunityBio were worth $47,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Copperwynd Financial LLC acquired a new position in ImmunityBio in the fourth quarter valued at approximately $79,000. Rafferty Asset Management LLC acquired a new position in ImmunityBio in the fourth quarter valued at approximately $3,714,000. Meridian Management Co. acquired a new position in ImmunityBio in the fourth quarter valued at approximately $46,000. Corient Private Wealth LLC lifted its holdings in ImmunityBio by 28.6% in the fourth quarter. Corient Private Wealth LLC now owns 223,430 shares of the company’s stock valued at $1,122,000 after acquiring an additional 49,729 shares during the last quarter. Finally, E Fund Management Co. Ltd. acquired a new position in ImmunityBio during the fourth quarter worth $198,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.

ImmunityBio Stock Down 11.1 %

NASDAQ:IBRX traded down $1.00 during trading hours on Tuesday, reaching $7.99. 14,954,729 shares of the stock were exchanged, compared to its average volume of 5,782,541. The business has a 50-day moving average of $5.34 and a two-hundred day moving average of $4.28. ImmunityBio, Inc. has a twelve month low of $1.25 and a twelve month high of $10.53. The company has a market capitalization of $5.41 billion, a price-to-earnings ratio of -6.89 and a beta of 1.23.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Tuesday, March 19th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). The business had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.03 million. On average, research analysts forecast that ImmunityBio, Inc. will post -0.68 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Piper Sandler upped their price target on ImmunityBio from $5.00 to $6.00 and gave the stock a “neutral” rating in a research note on Monday.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.